Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyell Immunopharma, Inc. (Nasdaq: LYEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lyell is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its filings give structured insight into how it reports clinical, financial, and corporate developments.
Among the key documents are Current Reports on Form 8‑K, where Lyell furnishes press releases on quarterly financial results and business highlights, including updates on pivotal trials of rondecabtagene autoleucel (ronde‑cel/LYL314) in relapsed and/or refractory large B-cell lymphoma and progress in its broader CAR T-cell pipeline. Other 8‑K filings describe material agreements, such as the Exclusive License Agreement granting Lyell rights to the GCC‑targeted CAR T-cell product candidate LYL273, and a Securities Purchase Agreement for a private placement of common stock and potential pre‑funded warrants to fund pivotal-stage trials.
Filings also detail unregistered sales of equity securities related to private placements, milestone share issuances following an acquisition, and equity consideration under licensing arrangements. Additional 8‑K items cover changes in key officers, including appointments and resignations in financial leadership roles, providing context on corporate governance and management structure.
On Stock Titan, these filings are complemented by AI-powered tools that can help summarize lengthy documents, highlight items such as financing terms, licensing economics, and clinical milestone triggers, and surface relevant sections across multiple reports. Users interested in LYEL can review Forms 8‑K and other periodic reports as they become available to track how Lyell discloses clinical progress, capital structure changes, and significant agreements connected to its CAR T-cell programs.
Lyell Immunopharma (LYEL) reported an insider equity award. The reporting person, who serves as President, CEO and Director, acquired 175,000 stock options on 10/27/2025 at an exercise price of $17.23, expiring on 10/26/2035.
Vesting is scheduled with 12.5% on April 27, 2026, and the remainder in equal monthly installments over the following 42 months, subject to continued service. Following the reported transactions, the insider beneficially owns 67,571 shares of common stock.
Lyell Immunopharma, Inc. reported that Chief Financial Officer Charles Newton, who also serves as the company’s principal financial and accounting officer, has decided to resign. His resignation will be effective October 31, 2025. The company states there were no disagreements between Mr. Newton and Lyell.
Lyell plans to conduct a search for a new CFO to take over its financial leadership. To support continuity, the company and Mr. Newton entered into a consulting agreement under which he may provide consulting services from the resignation date through April 30, 2026, unless either party ends the consultancy earlier.
Seely Lynn, who serves as President and CEO and a director of Lyell Immunopharma, reported the issuance and a subsequent sale of company common stock. Per performance-based restricted stock units granted on February 9, 2024, 40,000 shares were recorded as issued on 08/20/2025, with 20,000 shares issued immediately upon certification of performance and the remaining 20,000 shares scheduled for issuance on 08/20/2026 subject to continued service. The next day, 7,257 shares were sold automatically to cover tax withholding at a weighted average price of $10.544 (sales ranged $10.49 to $10.64). After these transactions the reporting person beneficially owned 67,571 shares.
Stephen J. Hill, Chief Operating Officer and director of Lyell Immunopharma (LYEL), reported two equity transactions: 8,000 shares of common stock were issued on 08/20/2025 upon vesting of performance-based restricted stock units (4,000 shares vested immediately; 4,000 remain subject to service-through vesting on 08/20/2026). The reporting person then sold 1,004 shares on 08/21/2025 to cover tax withholding at a weighted-average price of $10.544 (sale prices ranged $10.49–$10.64). Share counts reported: 16,849 shares beneficially owned after issuance and 15,845 shares after the tax-withholding sale.
Lyell Immunopharma insider trades by CFO Charles W. Newton: On 08/20/2025 Mr. Newton received 8,000 shares of Common Stock from performance-based restricted stock units that vested after certification by the compensation committee; 4,000 of those shares are immediately issued and 4,000 remain contingent for issuance on 08/20/2026 subject to continued service. Following the 08/20 issuance his beneficial ownership totaled 16,759 shares (direct).
On 08/21/2025 he sold 1,453 shares at a weighted average price of $10.544 per share to cover tax withholding. He also beneficially owns 10,000 shares indirectly through The Charles & Lisa Newton Living Trust, where he is co-trustee and co-grantor.
Lyell Immunopharma insider activity by Gary K. Lee: The company's Chief Scientific Officer received 8,000 shares on 08/20/2025 from performance-based restricted stock units, 4,000 of which vested upon certification of performance and 4,000 remain contingent on continued service through 08/20/2026. Following that issuance the reporting person beneficially owned 16,957 shares. On 08/21/2025 the reporting person sold 1,453 shares to satisfy tax withholding from the vested units at a weighted average price of $10.544 per share (sales ranged $10.49–$10.64). After the sale the beneficial ownership reported was 15,504 shares. The Form 4 was signed by an attorney-in-fact on 08/22/2025.
Lyell Immunopharma, Inc. Schedule 13G reports that Explore Investments LLC and Jeffrey P. Bezos each may be deemed to beneficially own 1,040,964 shares of Lyell common stock, representing 5.4% of the outstanding class as of the Event Date. Explore is the direct holder and Mr. Bezos is the sole member of Explore. Of the shares reported, 938,438 were acquired in the initial closing of a private placement on the Event Date. The filing notes the calculation basis of 14,808,006 total shares outstanding and disclaims beneficial ownership beyond the shares reported.
Lyell Immunopharma President and CEO Seely Lynn reported automatic sales of vested restricted stock units to satisfy tax withholding. The Form 4 shows 391 shares sold on 08/11/2025 at a weighted average price of $10.526 (range $10.045–$11.00) and 406 shares sold on 08/12/2025 at a weighted average price of $10.338 (range $10.120–$10.415).
All share amounts reflect a 1-for-20 reverse stock split effected on 05/30/2025. Following the reported transactions, the filing lists direct beneficial ownership of 35,234 shares after the first sale and 34,828 shares after the second; the sales are described as automatic to cover tax withholding on vested RSUs.
Stephen J. Hill, Chief Operating Officer and Director of Lyell Immunopharma (LYEL), reported two small disposition transactions tied to tax withholding for vested restricted stock units. On 08/11/2025 he sold 91 shares at a weighted average price of $10.526 (sale prices ranged $10.045 to $11.00), reducing his beneficial ownership to 8,943 shares. On 08/12/2025 he sold 94 shares at a weighted average price of $10.338 (sale prices ranged $10.120 to $10.415), reducing his beneficial ownership to 8,849 shares.
The Form 4 notes the shares sold were automatically disposed to satisfy tax withholding from vested RSUs, that Hill acquired 390 shares on 05/18/2025 under the company ESPP, and that LYEL effected a 1-for-20 reverse stock split on 05/30/2025; all share figures reflect that split. The Form 4 was signed by an attorney-in-fact on 08/13/2025.
Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma (LYEL), reported two routine sales of common stock on 08/11/2025 and 08/12/2025 to satisfy tax withholding obligations from vested restricted stock units. On 08/11/2025 he sold 131 shares at a weighted average price of $10.526 (range $10.045–$11.00), leaving 9,093 shares beneficially owned. On 08/12/2025 he sold 136 shares at a weighted average price of $10.338 (range $10.120–$10.415), leaving 8,957 shares beneficially owned. The Form 4 notes a 1-for-20 reverse stock split effective May 30, 2025 and inclusion of 390 ESPP shares acquired May 18, 2025. The filing was signed by an attorney-in-fact on 08/13/2025.